See more : Advantagewon Oil Corporation (AOC.CN) Income Statement Analysis – Financial Results
Complete financial analysis of PURE Bioscience, Inc. (PURE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PURE Bioscience, Inc., a leading company in the Household & Personal Products industry within the Consumer Defensive sector.
You may be interested
- Dogwood Therapeutics, Inc. (DWTX) Income Statement Analysis – Financial Results
- CREEK & RIVER Co., Ltd. (4763.T) Income Statement Analysis – Financial Results
- PT Berlian Laju Tanker Tbk (BLTA.JK) Income Statement Analysis – Financial Results
- CC Japan Income & Growth Trust plc (CCJS.L) Income Statement Analysis – Financial Results
- Kestrel Gold Inc. (KGC.V) Income Statement Analysis – Financial Results
PURE Bioscience, Inc. (PURE)
About PURE Bioscience, Inc.
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.96M | 1.88M | 1.85M | 3.93M | 6.92M | 1.91M | 1.77M | 1.83M | 1.29M | 729.00K | 550.00K | 820.00K | 812.00K | 464.18K | 1.44M | 728.26K | 1.49M | 336.39K | 200.43K | 155.81K | 263.50K | 2.59M | 3.21M | 2.41M | 1.66M | 3.40M | 1.70M | 1.00M | 800.00K |
| Cost of Revenue | 811.00K | 906.00K | 853.00K | 1.85M | 2.90M | 728.00K | 763.00K | 760.00K | 441.00K | 285.00K | 344.00K | 565.00K | 264.00K | 131.39K | 465.09K | 238.17K | 463.60K | 221.11K | 105.72K | 51.59K | 130.90K | 1.53M | 1.60M | 1.36M | 885.25K | 1.30M | 900.00K | 600.00K | 600.00K |
| Gross Profit | 1.15M | 971.00K | 1.00M | 2.08M | 4.02M | 1.18M | 1.01M | 1.07M | 848.00K | 444.00K | 206.00K | 255.00K | 548.00K | 332.79K | 971.04K | 490.10K | 1.02M | 115.28K | 94.71K | 104.21K | 132.60K | 1.06M | 1.61M | 1.05M | 776.21K | 2.10M | 800.00K | 400.00K | 200.00K |
| Gross Profit Ratio | 58.69% | 51.73% | 53.97% | 52.84% | 58.13% | 61.86% | 56.99% | 58.49% | 65.79% | 60.91% | 37.45% | 31.10% | 67.49% | 71.69% | 67.61% | 67.30% | 68.83% | 34.27% | 47.25% | 66.89% | 50.32% | 40.76% | 50.15% | 43.45% | 46.72% | 61.76% | 47.06% | 40.00% | 25.00% |
| Research & Development | 302.00K | 297.00K | 319.00K | 339.00K | 322.00K | 354.00K | 459.00K | 779.00K | 927.00K | 790.00K | 1.03M | 1.33M | 1.86M | 2.18M | 1.93M | 1.47M | 1.65M | 1.22M | 1.19M | 1.36M | 1.13M | 981.49K | 780.51K | 292.96K | 114.76K | 200.00K | 200.00K | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 4.05M | 0.00 | 6.42M | 7.59M | 6.30M | 6.98M | 7.29M | 8.32M | 5.72M | 7.44M | 6.52M | 4.93M | 5.46M | 5.14M | 3.74M | 2.61M | 1.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 927.94K | 694.07K | 805.63K | 899.15K | 570.16K | 427.45K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.98M | 4.30M | 4.11M | 4.05M | 3.70M | 6.42M | 7.59M | 6.30M | 6.98M | 7.29M | 8.32M | 5.72M | 7.44M | 6.52M | 5.86M | 6.16M | 5.95M | 3.74M | 2.61M | 1.76M | 1.63M | 3.28M | 2.77M | 2.57M | 2.31M | 1.50M | 2.40M | 1.90M | 700.00K |
| Other Expenses | 0.00 | -4.00K | 0.00 | -4.00K | 5.00K | 1.00K | 25.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 109.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 277.83K | 0.00 | 212.17K | 100.00K | 100.00K | 100.00K | 0.00 |
| Operating Expenses | 4.28M | 4.60M | 4.43M | 4.39M | 4.02M | 6.77M | 8.05M | 7.08M | 7.91M | 8.08M | 9.35M | 7.04M | 9.30M | 8.70M | 7.79M | 7.62M | 7.70M | 4.96M | 3.81M | 3.12M | 2.76M | 4.27M | 3.83M | 2.87M | 2.64M | 1.80M | 2.70M | 2.00M | 700.00K |
| Cost & Expenses | 5.09M | 5.51M | 5.28M | 6.24M | 6.91M | 7.50M | 8.82M | 7.84M | 8.35M | 8.37M | 9.70M | 7.61M | 9.57M | 8.83M | 8.25M | 7.86M | 8.17M | 5.18M | 3.91M | 3.17M | 2.89M | 5.80M | 5.43M | 4.23M | 3.52M | 3.10M | 3.60M | 2.60M | 1.30M |
| Interest Income | 0.00 | 14.00K | 6.00K | 4.00K | 5.00K | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 7.77K | 33.31K | 18.72K | 30.79K | 150.88K | 0.00 | 0.00 | 191.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 155.00K | 14.00K | 6.00K | 4.00K | 5.00K | 6.00K | 8.00K | 5.00K | 10.00K | 8.00K | 10.00K | 0.00 | 145.00K | -232.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 315.72K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 148.00K | 117.00K | 213.00K | 172.00K | 192.00K | 241.00K | 285.00K | 276.00K | 219.00K | 185.00K | 2.14M | 601.00K | 377.00K | 460.60K | 442.05K | 396.47K | 403.38K | 219.59K | 310.90K | 305.53K | 348.72K | 314.08K | 734.63K | 290.44K | 252.37K | 100.00K | 100.00K | -100.00K | 0.00 |
| EBITDA | -3.05M | -3.83M | -3.27M | -2.14M | 201.00K | -6.31M | -7.15M | -5.99M | -14.14M | -7.43M | -8.90M | -6.48M | -8.36M | -7.91M | -6.29M | -6.74M | -6.28M | -4.62M | -3.46M | -2.74M | -2.35M | -3.25M | -1.49M | -1.32M | -1.61M | 400.00K | -1.80M | -1.70M | -500.00K |
| EBITDA Ratio | -155.22% | -187.27% | -173.34% | -54.57% | 2.91% | -280.09% | -379.48% | -299.40% | 36.15% | -1,022.63% | -1,274.18% | -754.51% | -1,031.65% | -1,703.28% | -443.97% | -925.21% | -421.99% | -1,373.77% | -1,697.21% | -1,736.55% | -864.41% | -111.82% | -46.32% | -63.40% | -96.71% | 11.76% | -105.88% | -170.00% | -62.50% |
| Operating Income | -3.13M | -3.94M | -3.43M | -2.31M | 9.00K | -5.59M | -7.04M | -6.01M | 247.00K | -7.64M | -9.15M | -6.79M | -8.75M | -8.37M | -6.82M | -7.13M | -6.68M | -4.84M | -3.71M | -3.01M | -2.63M | -3.21M | -2.22M | -1.82M | -1.86M | 300.00K | -1.90M | -1.60M | -500.00K |
| Operating Income Ratio | -159.50% | -210.07% | -184.84% | -58.85% | 0.13% | -292.77% | -396.96% | -328.13% | 19.16% | -1,048.01% | -1,663.27% | -827.80% | -1,078.08% | -1,802.51% | -474.75% | -979.65% | -449.11% | -1,439.05% | -1,852.32% | -1,932.65% | -996.75% | -123.95% | -69.24% | -75.45% | -111.90% | 8.82% | -111.76% | -160.00% | -62.50% |
| Total Other Income/Expenses | -219.00K | -18.00K | 233.00K | -8.00K | 0.00 | -965.00K | -400.00K | -255.00K | -7.31M | 13.00K | 852.00K | -332.00K | -136.00K | 17.77K | 60.35K | 69.53K | 142.44K | 188.37K | 32.12K | -638.00 | -194.43K | 402.98K | -280.23K | -167.58K | 34.67K | 0.00 | 0.00 | 200.00K | 0.00 |
| Income Before Tax | -3.35M | -3.96M | -3.49M | -2.32M | 4.00K | -6.55M | -7.44M | -6.26M | -14.37M | -7.63M | -11.05M | -7.67M | -8.75M | -8.36M | -6.76M | -7.06M | -6.54M | -4.65M | -3.68M | -3.01M | -2.70M | -3.19M | -2.50M | -1.78M | -1.82M | 0.00 | 0.00 | -1.40M | 0.00 |
| Income Before Tax Ratio | -170.66% | -211.03% | -188.40% | -59.05% | 0.06% | -343.32% | -419.50% | -342.05% | -1,114.90% | -1,046.23% | -2,009.09% | -935.49% | -1,077.09% | -1,800.35% | -470.55% | -970.11% | -439.53% | -1,383.05% | -1,836.30% | -1,933.06% | -1,024.56% | -123.06% | -77.98% | -73.89% | -109.81% | 0.00% | 0.00% | -140.00% | 0.00% |
| Income Tax Expense | 0.00 | 10.00K | 6.00K | -68.56K | 10.00K | 7.00K | 33.00K | 255.00K | 7.31M | -13.00K | 1.90M | 883.00K | 136.00K | -17.77K | 2.52K | 2.40K | 2.40K | 2.40K | 132.39K | -1.16M | -318.77K | 74.35K | 224.88K | 1.60K | 800.00 | 0.00 | 0.00 | -200.00K | -100.00K |
| Net Income | -3.35M | -3.96M | -3.50M | -2.32M | -6.00K | -6.56M | -7.48M | -6.52M | -21.69M | -7.61M | -12.95M | -8.55M | -8.88M | -8.34M | -6.76M | -7.07M | -6.54M | -4.65M | -3.81M | -1.85M | -2.38M | -3.26M | -2.73M | -1.78M | -1.83M | 300.00K | -1.90M | -1.20M | -400.00K |
| Net Income Ratio | -170.66% | -211.03% | -188.72% | -59.05% | -0.09% | -343.69% | -421.36% | -355.98% | -1,682.31% | -1,044.44% | -2,354.91% | -1,043.17% | -1,093.84% | -1,796.53% | -470.73% | -970.43% | -439.70% | -1,383.77% | -1,902.35% | -1,185.53% | -903.58% | -125.93% | -84.99% | -73.96% | -109.86% | 8.82% | -111.76% | -120.00% | -50.00% |
| EPS | -0.03 | -0.04 | -0.04 | -0.03 | 0.00 | -0.09 | -0.11 | -0.10 | -0.38 | -0.19 | -0.51 | -0.79 | -1.58 | -1.79 | -1.57 | -1.85 | -1.90 | -1.52 | -1.49 | -0.92 | -1.55 | -2.86 | -2.85 | -2.24 | -3.01 | 0.47 | -3.92 | -2.88 | -1.12 |
| EPS Diluted | -0.03 | -0.04 | -0.04 | -0.03 | 0.00 | -0.09 | -0.11 | -0.10 | -0.38 | -0.19 | -0.51 | -0.79 | -1.58 | -1.79 | -1.57 | -1.85 | -1.90 | -1.52 | -1.49 | -0.92 | -1.55 | -2.86 | -2.85 | -2.24 | -1.81 | 0.31 | -3.92 | -2.88 | -1.12 |
| Weighted Avg Shares Out | 111.86M | 111.40M | 88.84M | 87.17M | 82.21M | 72.88M | 67.28M | 63.49M | 56.83M | 39.75M | 25.61M | 10.84M | 5.62M | 4.67M | 4.32M | 3.82M | 3.44M | 3.06M | 2.56M | 2.01M | 1.53M | 1.14M | 955.04K | 795.64K | 605.61K | 637.50K | 484.69K | 416.67K | 357.14K |
| Weighted Avg Shares Out (Dil) | 111.86M | 111.40M | 88.84M | 87.17M | 84.61M | 72.88M | 67.28M | 63.49M | 56.83M | 39.75M | 25.61M | 10.84M | 5.62M | 4.67M | 4.32M | 3.82M | 3.44M | 3.06M | 2.56M | 2.01M | 1.53M | 1.14M | 955.04K | 795.64K | 1.01M | 637.50K | 484.69K | 416.67K | 357.14K |
PURE Bioscience Announces Distribution Agreement with AFCO, a Zep Company
EL CAJON, Calif.--(BUSINESS WIRE)-- #AFCO--PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, and AFCO, a Zep Company (“AFCO”), have entered into a multi-year distribution agreement for the purchase...
PURE Bioscience Announces Distribution Agreement with Quip Laboratories
EL CAJON, Calif.--(BUSINESS WIRE)-- #AALAS--PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, and Quip Laboratories, Inc. (“Quip Labs”), have entered into a multi-year distribution agreement for the purchase...
PURE Bioscience Reports Fiscal 2024 Financial Results
EL CAJON, Calif.--(BUSINESS WIRE)-- #Biofilm--PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2024. Summary of Results –...
PURE Bioscience Announces Distribution Agreement with Madison Chemical Co., Inc.
EL CAJON, Calif.--(BUSINESS WIRE)-- #Antimicrobial--PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, and Madison Chemical Co., Inc. (“Madison Chemical”), have entered into a multi-year distribution agreement for the...
PURE Bioscience Announces Distribution Agreement with Zee Company
EL CAJON, Calif.--(BUSINESS WIRE)-- #Biofilm--PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), has entered into a multi-year distribution agreement with Tennessee-based Zee Company to purchase and sell PURE's patented antimicrobial products. This agreement will allow PURE, the non-toxic...
PURE Bioscience Announces Distribution Agreement with ChemStation
EL CAJON, Calif.--(BUSINESS WIRE)-- #Biofilm--PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, and ChemStation Buyers Association, Inc. (“ChemStation”), have entered into a multi-year distribution agreement for the purchase...
PURE Bioscience to Unveil its Newest Food Safety Solutions at the Annual International Association for Food Protection Meeting
EL CAJON, Calif.--(BUSINESS WIRE)-- #Biofilm--PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, is set to unveil its newest food safety solutions at the 2024 International Association for Food Protection (IAFP) show in Long...
PURE Bioscience Announces an International Supply and License Agreement with AgroVet Alliance
EL CAJON, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, and AgroVet Alliance, FZE (“AVA”), have entered into a multi-year international supply and license agreement for the...
PURE Bioscience Reports Fiscal Third Quarter 2024 Financial Results
EL CAJON, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2024. Summary of Results –...
PURE Bioscience Appoints Darin Zehr to Board of Directors
EL CAJON, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported the appointment of Darin Zehr to its Board of Directors, effective as of May 1,...
Source: https://incomestatements.info
Category: Stock Reports